(no more than 30 lines of text): Pancreatic cancer is the fourth-leading cause of cancer death in the U.S. Over 80% of patients present with incurable disease, and the vast majority live for <12 months. The high mortality of pancreatic ductal adenocarcinoma (PDAC), the most common form of pancreatic cancer, is largely a consequence of diagnosis at an advanced stage when the tumor is no longer resectable for cure. However, symptoms rarely develop with early disease, and established risk factors for PDAC, such as tobacco smoking, obesity, chronic pancreatitis, diabetes, and family history of PDAC, are insufficient to risk stratify the population for disease screening. Experimental studies indicate that more than a decade elapses from formation of the founder malignant clone to a patient's diagnosis, suggesting a window of opportunity for early detection. Nevertheless, no early detection markers have advanced to clinical use, in part, because little infrastructure has been developed to facilitate rigorous investigation of promising candidates. To address the critical goal of PDAC early detection, we have brought together investigators with a long track-record of collaborative innovation to form the Pancreatic Cancer Circulating Biomarker (Pan-C2-Bio) Consortium. Within this Consortium, we join ongoing patient biospecimen collection at five large cancer centers with four highly promising early detection technologies and sophisticated computer modeling to define a non-invasive PDAC screening strategy. The Consortium will work to achieve three primary goals: (1) generation of a large, unified, thoroughly-annotated human and murine sample bank for testing of early detection markers, (2) definitive evaluation of four highly promising PDAC early detection markers for near-term clinical utility, including circulating cell-free DNA mutations and methylation patterns, cancer-derived exosomes, and metabolism markers, and (3) identification of biomarker-based screening strategies to facilitate early cancer diagnosis in high-risk groups and the general population. Thus, the work proposed by the Pan-C2-Bio Consortium will deliver much-needed biospecimen resources for early detection studies, provide evidence for (or against) the utility of four highly promising PDAC early detection technologies, and demonstrate how new biomarkers can be integrated with previously characterized risk factors to identify individuals for disease screening. With this work, we look to reduce mortality from pancreatic cancer by identifying those at highest risk and diagnosing subclinical disease when curative therapies can be applied.

Public Health Relevance

(2-3 sentences, relevance to public health): Pancreatic cancer is a major cause of cancer death in the United States, due largely to its late stage at diagnosis. We join together five large cancer centers with a track-record of innovation and collaboration to accomplish three primary goals: (1) generate thoroughly-annotated human and murine sample banks for testing of early detection markers, (2) rigorously evaluate highly promising early detection markers for near- term clinical utility, including circulating cell-free DNA, exosomes, and metabolism markers, and (3) construct risk stratification models to integrate early detection markers into screening programs for high-risk groups and the general population. Thus, the goal of this proposal to is reduce pancreatic cancer mortality by diagnosing the cancer when it is still at an early stage and amenable to curative treatments.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project--Cooperative Agreements (U01)
Project #
1U01CA210171-01
Application #
9187512
Study Section
Special Emphasis Panel (ZCA1-GRB-I (M1))
Program Officer
Rinaudo, Jo Ann S
Project Start
2016-07-15
Project End
2021-06-30
Budget Start
2016-07-15
Budget End
2017-06-30
Support Year
1
Fiscal Year
2016
Total Cost
$798,046
Indirect Cost
$217,421
Name
Dana-Farber Cancer Institute
Department
Type
DUNS #
076580745
City
Boston
State
MA
Country
United States
Zip Code
02215
Perez, Kimberly; Clancy, Thomas E; Mancias, Joseph D et al. (2017) When, What, and Why of Perioperative Treatment of Potentially Curable Pancreatic Adenocarcinoma. J Clin Oncol 35:485-489
Gilbert, J W; Wolpin, B; Clancy, T et al. (2017) Reply to the letter to the editor 'Borderline resectable pancreatic cancer: an evolving concept' by Petrucciani et al. Ann Oncol 28:2316
Bao, Ying; Prescott, Jennifer; Yuan, Chen et al. (2017) Leucocyte telomere length, genetic variants at the TERT gene region and risk of pancreatic cancer. Gut 66:1116-1122
Qian, Zhi Rong; Rubinson, Douglas A; Nowak, Jonathan A et al. (2017) Association of Alterations in Main Driver Genes With Outcomes of Patients With Resected Pancreatic Ductal Adenocarcinoma. JAMA Oncol :
Khalaf, Natalia; Yuan, Chen; Hamada, Tsuyoshi et al. (2017) Regular Use of Aspirin or Non-Aspirin Nonsteroidal Anti-Inflammatory Drugs Is Not Associated With Risk of Incident Pancreatic Cancer in Two Large Cohort Studies. Gastroenterology :
Lindström, Sara; Loomis, Stephanie; Turman, Constance et al. (2017) A comprehensive survey of genetic variation in 20,691 subjects from four large cohorts. PLoS One 12:e0173997
Townsend, Mary K; Bao, Ying; Poole, Elizabeth M et al. (2016) Impact of Pre-analytic Blood Sample Collection Factors on Metabolomics. Cancer Epidemiol Biomarkers Prev 25:823-829
Jeong, Sangmoo; Park, Jongmin; Pathania, Divya et al. (2016) Integrated Magneto-Electrochemical Sensor for Exosome Analysis. ACS Nano 10:1802-9
Paweletz, Cloud P; Sacher, Adrian G; Raymond, Chris K et al. (2016) Bias-Corrected Targeted Next-Generation Sequencing for Rapid, Multiplexed Detection of Actionable Alterations in Cell-Free DNA from Advanced Lung Cancer Patients. Clin Cancer Res 22:915-22
Mayers, Jared R; Torrence, Margaret E; Danai, Laura V et al. (2016) Tissue of origin dictates branched-chain amino acid metabolism in mutant Kras-driven cancers. Science 353:1161-5

Showing the most recent 10 out of 16 publications